Growth inhibitory effects of thromboxane antagonists on breast cancer cell lines: a preliminary study.
Marshall
K
K
Postgraduate Pharmacology, School of Pharmacy, University of Bradford, United Kingdom.
Lane
K
K
Senior
J
J
D001943:Breast Neoplasms; D019086:Bridged Bicyclo Compounds, Heterocyclic; D002455:Cell Division / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D005231:Fatty Acids, Unsaturated; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000494:pharmacology*; D010648:Phenylacetates / Q000494:pharmacology*; D011465:Prostaglandins, Synthetic / Q000494:pharmacology*; D013449:Sulfonamides / Q000494:pharmacology*; D013931:Thromboxanes / Q000037:antagonists & inhibitors*; D014407:Tumor Cells, Cultured
D019086:Bridged Bicyclo Compounds, Heterocyclic; D005231:Fatty Acids, Unsaturated; D006834:Hydrazines; D010648:Phenylacetates; D011465:Prostaglandins, Synthetic; D013449:Sulfonamides; D013931:Thromboxanes; C045749:SQ 29548; C045332:EP 092; C051762:daltroban